Prism TPO Launches Drug Pricing Transparency Platform for Independent Oncology Practices

Prism TPO today announced the launch of its pricing transparency platform, designed to give independent oncology practices clear visibility into true net drug economics—capabilities historically challenging to access within the GPO and distributor ecosystem.

Prism’s platform integrates live distributor pricing, GPO contract economics, and reimbursement data into a unified view of drug costs. By normalizing complex pricing inputs and contextualizing them against reimbursement benchmarks, the platform enables practices to assess profitability, compare therapeutic alternatives, and make informed purchasing decisions.

Practices rely on distributor price lists, manual reporting, and spreadsheets to understand the true net economics of their purchases. The portal eliminates these siloed workflows with a single, purpose-built system for faster, smarter decision-making.

“We built Prism’s Transparency Portal to turn fragmented drug pricing inputs into a single, reliable view for the practice,” said Ina Ochoche, Head of Engineering. “As pricing complexity and volatility increase, immediate clarity into true net economics has become essential—and this platform aims to deliver that insight without the spreadsheets or delays.”

The platform is live today and was developed in close partnership with customers. Planned roadmap enhancements include predictive modeling to enable purchase forecasting, anomaly detection and scenario planning at scale. 

“Prism enhances our existing purchasing process by providing visibility into true net drug economics,” said Jonathan Hanke, Director of Pharmacy at Cancer Care Specialists of Illinois. “With immediate insight into profitability and pricing changes, we’re able to make purchasing decisions with even greater confidence.”

By operationalizing upfront, trustworthy, and transparent drug pricing, Prism’s technology delivers on the company’s founding mission to bring clarity to a historically opaque system. Rather than relying on delayed reports or incomplete signals, independent oncology practices can now operate with confidence—making purchasing decisions grounded in accurate, reliable, and timely economic insight.

Media Contact
Prism TPO
press@prismtpo.com